FDA proposes new lead limits for baby food to reduce potential risks to children’s health

FDA proposes new lead limits for baby food to reduce potential risks to children’s health


Jgi/jamie Grill | Tetra Images | Getty Images

The Food and Drug Administration proposed new limits Tuesday on lead in baby food, in an effort to reduce exposure to a toxin that can impair childhood development.

The lead limits apply to processed food consumed by children younger than two years old. In a statement, FDA Commissioner Dr. Robert Califf said the limits would reduce lead exposure from these foods by as much as 27%.

related investing news

Cowen says buy Regeneron, success of drugs could help pharmaceutical stock

CNBC Pro

The proposed lead limits are not legally binding on the industry, but the FDA said it would use them as a factor in deciding whether to take enforcement action against a company for selling contaminated food.

The agency proposed the following lead concentration limits for baby food:

  • 10 parts per billion for fruits, vegetables, yoghurts, custards and puddings, mixtures, and single ingredient meats. This would reduce exposure by 26%.
  • 20 parts per billion for root vegetables. This would reduce exposure by 27%.
  • 20 parts per billion for dry cereals. This would reduce exposure by 24%.

Lead is toxic and particularly dangerous for young children. It can impair brain development and the nervous system, resulting in learning disabilities and behavioral difficulties.

Lead exposure through food among children ages 1 to 3 has declined 97% since the 1980s, according to the FDA. Though progress has been made over the years, the agency launched an effort in 2021 to reduce the levels of lead, arsenic, cadmium and mercury in children’s food to the greatest extent possible.

Food consumed by children can contain lead due to contaminated water or soil, industrial activity and old lead-containing equipment used to make food, according to the FDA. The agency said it’s not possible to completely remove lead from the food supply, but the limits should push industry to take measures to reduce its presence as much as possible.

CNBC Health & Science

Read CNBC’s latest global health coverage:



Source

2026 will bring more GLP-1 weight loss pills — and new habits. These stocks are poised to benefit
Health

2026 will bring more GLP-1 weight loss pills — and new habits. These stocks are poised to benefit

The ripple is about to become a wave. Right now, there are numerous barriers for people who are considering treating their obesity with GLP-1 drugs. Early on, there were manufacturing bottlenecks that resulted in short supplies of Novo Nordisk ‘s Wegovy and Eli Lilly ‘s Zepbound. There were insurance coverage issues for these pricey treatments, […]

Read More
Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale
Health

Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale

Jim Cramer says don’t sweat Novo Nordisk’s head start over Club holding Eli Lilly in the obesity pill market. Eli Lilly stock slipped about half a percent this morning, while Novo Nordisk shares surged more than 8% after becoming the first to secure FDA approval for a GLP-1 weight-loss pill. “[Novo] got approval ahead of […]

Read More
FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk
Health

FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk

The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, Nov. 24, 2025. Tom Little | Reuters The U.S. Food and Drug Administration on Monday approved the first-ever GLP-1 pill for obesity from Wegovy maker Novo Nordisk, a landmark decision that health experts […]

Read More